Sweet Dreams

. . . The much-anticipated launch of LUNESTA(TM), an insomnia treatment, by Sepracor (Nasdaq: SEPR) is expected in the first few weeks of April. So far, more than 40,000 retail pharmacies have already placed orders with wholesalers. Why all the anticipation? LUNESTA is the first and only sleep medication approved for long- term use. It has proven effective in long-term, continuous treatment, with a lack of significant rebound when therapy is discontinued. In addition, clinical studies showed no measurable next-day residual effects in most patients. Insomnia is an enormous market with an estimated 100 million adult Americans suffering from either chronic or occasional insomnia. In the past decade, Ambien has been the blockbuster insomnia drug, however, it is only recommended for short-term use.

From: www.InvestingIN.com/biotech

View from the Cockpit

. . . Global ePoint (Nasdaq:GEPT) will supply GE Capital Aviation Service with video surveillance systems for cockpits. Global's Airworks Cockpit Door Surveillance System will be installed on eight AirBus A320 aircraft. The Airworks Cockpit Door Surveillance System provides pilots and crew members with a state-of-the-art tool to assess potential emergency situations. Global ePoint's growth strategy focuses on the design, manufacturing, sales and distribution of digital video surveillance systems for the law enforcement, military, aviation and homeland security markets.

From: www.InvestingIN.com/security

New Products. New Coverage.

. . New Products. New Coverage. Morgan Keegan initiated coverage of RAE Systems (AMEX:RAE) with an outperform rating. RAE is a global developer and manufacturer of rapidly deployable, multi-sensor chemical detection monitors and networks for homeland security and industrial applications. In the current quarter, the company has introduced a number of products, including the HazRAE Handheld Wireless Decision Support System, PlumeRAE Integrated Decision Support System, and GammaRAE II Low-Cost Gamma Radiation Detector.

From: www.SmallcapRecap.com

Is Lithium the New Oil?. . . The Titanic Rises Again

. . . Is Lithium the New Oil? Lithium-powered vehicles will have a larger presence than ever before at the New York, International Automobile Show, the largest such show in North America. At the show, Hybrid Technologies (OTCBB: HYBT) will unveil its fleet of emissions-free, lithium powered vehicles. Hybrid may be catching a tailwind of legislation, growing concern about oil dependence and star power as high-powered celebrities such as Leo DiCaprio proudly talk about their hybrid cars.

. . . The Titanic rises again. Premier Exhibitions, Inc. (BULLETIN BOARD: PXHB) brings its Titanic ... The Artifact Exhibition to the Tropicana Resort & Casino in Las Vegas. It will run through October 31st, 2005. The exhibit includes authentic artifacts rescued from the wreck site, which lies two and a half miles beneath the North Atlantic Ocean. The Artifact Exhibition has been seen by more than 15 million visitors worldwide, making it the most highly attended and enduring traveling exhibition in history. Premier Exhibitions, Inc., a major provider of museum quality touring exhibitions throughout the world, is the only company permitted by law to recover objects from the wreck of the Titanic.

Opportunities in Dirt...Irish Take Over New Jersey

. . . Opportunities in Dirt. . . Fans of dirt racing are extremely loyal and pack dirt racing events around the country. That's why Motor Sports Racing, Inc. d/b/a DIRT MotorSports (OTCBB:BMSR - News), added the Lernerville Speedway in Sarver, Pa to its portfolio of existing tracks. It is part of the company's expansion strategy in the Mid-Atlantic and across the country." Recently the company signed agreements with the country's top 15 sprint car drivers to participate in the 2005 World of Outlaws Sprint Series®, including 19-time World of Outlaws Sprint Series Champion Steve Kinser.

. . . Irish take over New Jersey. . . Trinity Biotech (Nasdaq: TRIB), an Ireland-based company which makes a broad line of test kits used to detect infectious diseases, sexually transmitted diseases, blood coagulation disorders, and autoimmune diseases, acquired Research Diagnostics Inc in New Jersey. The range of products RDI provides encompasses monoclonal and polyclonal antibodies, antigens, proteins, enzymes and immunochemicals employed in the areas of cancer, cardiac, fertility and infectious disease diagnosis. RDI's operations will be integrated with Fitzgeralds, a company with a similar product line, that Trinity acquired last year. Annual revenues last year increased 22% over the previous year, and Q4 revenues increased by 42% compared to the same period last year.

From: www.SmallcapRecap.com